TOPLINE

Brodalumab produced rapid and sustained disease control over 52 weeks in a real-world cohort of adults with moderate-to-severe plaque psoriasis.

METHODOLOGY

• Researchers conducted a multicentre, observational study of 858 adults (median age, 49.7 years; 70.6% men) from the Italian Landscape Psoriasis database who received brodalumab for moderate-to-severe plaque psoriasis.
• The Psoriasis Area and Severity Index (PASI) score was assessed at baseline and weeks 16, 32, and 52; overall, 764 patients had complete longitudinal data.
• Among the 764 patients, the median absolute PASI score at baseline was 14.7.
• The study outcome was the normalised cumulative clinical benefit over 52 weeks.
• The researchers also assessed the absolute PASI score and percentage PASI score improvement at each follow-up visit; PASI 75 (at least a 75% improvement in the PASI score from baseline), PASI 90 (at least a 90% improvement in the PASI score from baseline), and PASI 100 (complete clearance) response rates; and clearance-equivalent days.

TAKEAWAY

• The median normalised cumulative clinical benefit was 97.4% over 52 weeks.
• The median absolute PASI score was 0 at weeks 16, 32, and 52. The median percentage PASI score improvement was 100% at all follow-ups.
• At week 52, 93.1% of patients achieved PASI 75, and 86.1% and 70.4% reached PASI 90 and PASI 100, respectively.
• The median calculated clearance-equivalent time was 300 days.

IN PRACTICE

"In this large multicentre real-world study, brodalumab provided deep and sustained clinical improvement over 52 weeks, with a median cumulative clinical benefit of 97.4% and 300 clearance-equivalent days," the authors wrote.

SOURCE

The study was led by Luca Potestio, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy. It was published online on September 17, 2026, in Dermatology and Therapy.

LIMITATIONS

The study was limited by its retrospective design, residual confounding, possible selection bias, and the PASI assessment at only four timepoints. The significant ceiling effect and the lack of an active comparator limited the interpretation of treatment benefits.

DISCLOSURES

The study did not receive any funding. Several authors reported serving as consultants, advisory board members, or speakers and receiving research grants or honoraria from pharmaceutical companies, including Accord, Almirall, Amgen, Eli Lilly, Johnson & Johnson, Novartis, Pierre Fabre, and UCB Pharma. Full disclosures are available in the original source article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.